27 March 2017
Geneva Teams with Phelix Therapeutics and USAMRIID
Phelix Therapeutics is launching a collaboration with The Geneva Foundation and The United States Army Medical Research Institute of Infectious Diseases (USAMRIID) for continued research of a treatment for SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome) via Phelix’s “novel viral fusion inhibitors for treating SARS/MERS coronaviruses”.
SARS and MERS are coronaviruses that can cause life-threatening gastrointestinal, respiratory, and neurological symptoms. Both have both been labeled as “likely to cause future epidemics” by the World Health Organization. However, there currently are no FDA-approved drugs available for treatment.
Geneva’s support of this program will continue the organization’s work in the field of infectious disease research, one of Geneva’s primary research areas. Geneva remains committed to offering our partners a superior level of service and expertise in our support and management of federally-funded research, conduct of Phase I-IV clinical trials, and event management capabilities.
PHELIX USAMRIID GENEVA PRESS RELEASE 3 27 2017 FOR IMMEDIATE RELEASE